Should You Buy Earth Science Tech, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Earth Science Tech, Inc. (ETST) scores a robust 8.5/10 on our 32-signal Quality of Company framework. At the current market price of $0.09 and a $26M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 4 of 9 CirclFi valuation models project upside for Earth Science Tech, Inc. (ETST) at $0.09 — the model consensus leans bearish, with a Quality Score of 8.5/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Earth Science Tech, Inc. (ETST) in 2026?
What Is the Bull Case vs the Bear Case for Earth Science Tech, Inc. (ETST)?
| Bull case — $0.17 target (+86.2%) | Bear case — $0.04 target (-59.6%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Earth Science Tech, Inc.'s quality score of 8.5/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.04 (-59.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $0.17 (+86.2%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +145.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Earth Science Tech, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: drug pricing legislation represents a meaningful risk for Earth Science Tech, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does ETST Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: HLN · BCRX · ALKS · SIGA · PAHC · PBH · ACB · TLPH · BUDZ · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like ETST on Quality?
Closest companies to ETST’s Quality of Company score of 8.5/10, across all industries.
- ARCO — Arcos Dorados Holdings Inc. (QOC 8.5) · analysis
- PLOW — Douglas Dynamics, Inc. (QOC 8.5) · analysis
- NWPX — NWPX Infrastructure, Inc. (QOC 8.5) · analysis
- CORT — Corcept Therapeutics Incorporated (QOC 8.5) · analysis
- ENSG — The Ensign Group, Inc. (QOC 8.5) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does ETST Appear In?
So Is Earth Science Tech, Inc. (ETST) Worth Buying in 2026?
Caution dominates our read on Earth Science Tech, Inc. at $0.09. 5 of 9 models see limited upside or outright downside, with the median fair value at $0.09 (-7.1%). Quality at 8.5/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Earth Science Tech, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ETST Stock?
Should I buy ETST stock right now?
Based on CirclFi's multi-model analysis, 4 of 9 models see upside for ETST at $0.09. The models are divided, which means the investment case depends heavily on your assumptions about Earth Science Tech, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Earth Science Tech, Inc.?
Key risks include: wide model disagreement (361% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does ETST compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, ETST holds a Quality Score of 8.5/10. Comparable companies include HLN (QOC 8.5), BCRX (QOC 8.4), ALKS (QOC 8.6). The relative ranking helps investors identify whether ETST offers better fundamental quality than alternatives in the same sector.
Is ETST a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ETST's Quality Score of 8.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ETST at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.04 to $0.17. At $0.09, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ETST.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad